Statement: Cohort 1 of the primary trial had 25% more patients experiencing Cholecystitis than cohort 2.
Primary_evidence: Adverse Events 1:   Total: 13/24 (54.17%)   FEBRILE NEUTROPENIA 5/24 (20.83%)   HAEMATOTOXICITY 0/24 (0.00%)   NEUTROPENIA 3/24 (12.50%)   LYMPHADENOPATHY 0/24 (0.00%)   PERICARDIAL EFFUSION 1/24 (4.17%)   ATRIAL FIBRILLATION 1/24 (4.17%)   APLASIA 0/24 (0.00%)   NAUSEA 0/24 (0.00%)   PYREXIA 1/24 (4.17%)   EXTRAVASATION 0/24 (0.00%)   CHOLECYSTITIS 1/24 (4.17%)   PATHOLOGICAL FRACTURE 1/24 (4.17%) Adverse Events 2:   Total: 6/24 (25.00%)   FEBRILE NEUTROPENIA 0/24 (0.00%)   HAEMATOTOXICITY 1/24 (4.17%)   NEUTROPENIA 0/24 (0.00%)   LYMPHADENOPATHY 1/24 (4.17%)   PERICARDIAL EFFUSION 0/24 (0.00%)   ATRIAL FIBRILLATION 0/24 (0.00%)   APLASIA 1/24 (4.17%)   NAUSEA 1/24 (4.17%)   PYREXIA 0/24 (0.00%)   EXTRAVASATION 1/24 (4.17%)   CHOLECYSTITIS 0/24 (0.00%)   PATHOLOGICAL FRACTURE 0/24 (0.00%)